Quantitative Investment Management LLC Makes New $992,000 Investment in United Therapeutics Corporation $UTHR

Quantitative Investment Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,831 shares of the biotechnology company’s stock, valued at approximately $992,000.

Several other large investors have also recently made changes to their positions in the business. Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at $277,000. Cerity Partners LLC raised its position in United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia raised its position in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, August 31st. The shares were sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $165,819,572.87. This trade represents a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 414,075 shares of company stock worth $221,222,045. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Up 0.5%

United Therapeutics stock opened at $512.70 on Wednesday. The firm has a 50-day moving average of $529.27 and a 200-day moving average of $539.68. The firm has a market cap of $21.99 billion, a P/E ratio of 18.34, a P/E/G ratio of 2.55 and a beta of 0.56. United Therapeutics Corporation has a 1-year low of $375.61 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 EPS. Research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on UTHR. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.